帕罗西汀对冠心病患者冠状动脉支架植入术后抑郁障碍的临床疗效

The clinical results of paroxetine hydrochloride on depressive disorder in patients with coronary heart, disease after coronary artery stent implantation

目的探讨冠心病患者冠状动脉支架植入术后抑郁障碍的发生情况，并观察帕罗西汀抗抑郁治疗对患者抑郁障碍的疗效。方法采用抑郁自评量表（SDS）、汉密尔顿抑郁量表（HAMD-24）评定冠心病患者冠状动脉支架植入术前、术后1个月患者的抑郁障碍的发生情况。观察冠状动脉支架植入术后1个月经SDS、HAMD-24共同评定为抑郁障碍的患者，帕罗西汀治疗组和谷维素对照组的临床疗效。结果冠心病合并抑郁障碍的比例达39．1％，冠状动脉支架植入后1个月抑郁障碍发生率为43．6％；术前、术后1个月SDS、HAMD-24抑郁评分差异无显著性（P〉0．05）；帕罗西汀治疗3个月后SDS、HAMD-24抑郁评分较干预前明显降低（P〈0．01），并且明显低于对照组（P〈0．01）。结论冠状动脉支架植入后患者发生抑郁障碍的比例轻度增加，但差异无显著性；盐酸帕罗西汀治疗能够减轻患者的抑郁障碍程度。

Objective To, investigate the prevalence rate of depressive disorder in patients with coronary heart disease （CHD） after coronary artery stent implantation and the results of influence of paroxetine hydrochloride. Methods Totally 156 patients who underwent coronary artery stent implantation were assessed with SDS and HAMD-24 before and after the treatment. 68 patients with depressive disorder after coronary artery stent implantation were divided into two groups at random, one of which was prescribed paroxetine hydrochloride 20 - 60mg once a day on the basis of routine cardiac drug therapy for 3 months and the other oryzanol tablets. Results The prevalence rate of depressive disorder in patients with coronary heart disease was 39.1%. The depressive exponent of SDS and HAMD-24 after coronary artery stent implantation wasnt was lower than that of before . The post-treatment depressive exponent of SDS and HAMD-24 in paroxetine hydrochloride group was lower than that of before, and lower than that of oryzanol tablets. Conclusion The prevalence rate of depressive disorder in patients with CHD is high. coronary artery stent implantation can＇ t improve the depressive symptoms of these patients. Anti-depression therapy of paroxetine hydrochloride can decrease depressive exponent of CHD patients with depressive disorder.